Related Experiment Video

Updated: Aug 10, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

Biologics for Reducing Cardiovascular Risk in Psoriasis Patients

Hitoshi Terui1, Yoshihide Asano1

  • 1Department of Dermatology, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan.

Journal of Clinical Medicine
|February 11, 2023
PubMed

Insights

Psoriasis patients have a high risk of cardiovascular disease (CVD). Biologics used to treat psoriasis may also reduce CVD risk by targeting inflammatory pathways linked to atherosclerosis.

Area of Science:

  • Dermatology
  • Cardiology
  • Immunology

Background:

  • Psoriasis is a chronic inflammatory skin condition frequently co-occurring with cardiovascular disease (CVD).
  • CVD is a leading cause of death in psoriasis patients, necessitating risk reduction strategies.
  • Psoriatic inflammation is increasingly recognized as a contributor to systemic cardiovascular risk.

Purpose of the Study:

  • To review cardiovascular risk factors in psoriasis patients.
  • To explore the link between psoriatic inflammation and atherosclerosis.
  • To evaluate the potential of biologic therapies in mitigating CVD risk in psoriasis.

Main Methods:

  • Literature review of studies on psoriasis, cardiovascular disease, and biologic therapies.
  • Analysis of the role of inflammatory cytokines (TNF-α, IL-12/23, IL-17) in atherosclerosis.
  • Synthesis of evidence on the cardiovascular benefits of psoriasis biologics.

Main Results:

  • Psoriasis patients exhibit a high prevalence of traditional cardiovascular risk factors.
  • Inflammatory mediators in psoriasis may directly contribute to the development of atherosclerosis.
  • Biologic therapies targeting key inflammatory cytokines show promise in improving both psoriasis and cardiovascular health.

Conclusions:

  • Cardiovascular risk management is crucial for psoriasis patients.
  • Targeting specific inflammatory pathways with biologics may offer a dual benefit for skin and cardiovascular health.
  • Further research is warranted to confirm the long-term cardiovascular protective effects of biologics in psoriasis.

Keywords:
biologicscardiovascular diseasepsoriasissystemic therapy

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

474
Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration14:49

Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration

Published on: September 29, 2018

42.1K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
204
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
24
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
240
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
65
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
730